We found discrepancy in growth outcomes between those who received GnRH analogs and those who did not which may be attributed to either the late initiation of GnRH therapy or the presence of significant hyperandrogenism, which, in turn, necessitated non-physiological steroid dosing, potentially affecting growth trajectories. Here, GNRH1 is linked to hyperandrogenism.